<DOC>
	<DOCNO>NCT00982657</DOCNO>
	<brief_summary>The safety tolerability CVX-060 establish first-in-human clinical trial , CVX-060-101 . Thus , phase Ib/II trial ass safety pharmacokinetics ( PK ) profile combine CVX-060 sunitinib patient advance solid tumor , subsequently assess treatment efficacy combination treatment , well sunitinib alone patient advance renal cell carcinoma ( mRCC ) .</brief_summary>
	<brief_title>A Trial Of CVX-060 , An Anti-Angiogenic COVX-Body , In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>On 23-Nov-2010 , B1131001 ( CVX-060-102 ) close enrollment due emerge clinical data lead re-assessment strategic goal PF-04856884 program . The study enrol Phase 1b portion . Subsequently , 25-Oct-2012 , due data safety signal separate clinical trial PF-04856884 ( CVX-060 ) , PF-04856884 study discontinue ongoing patient B1131001 permit remain study reduce PF-04856884 dose determine derive clinical benefit .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm advanced/metastatic solid tumor Having receive least 1 prior systemic therapy treatment advanced/metastatic solid tumor Histologically cytologically confirm renal cell carcinoma clear cell histology evidence metastasis ( No previous systemic therapy treatment metastatic renal cell carcinoma ) Adequate laboratory test Eastern Cooperative Oncology Group ( ECOG ) 01 , Life expectancy &gt; = 12 week age &gt; = 18 year Patients intolerant prior antiangiogenic agent Recent history bleed bleed disorder History tumor brain History heart problem History severe allergic reaction antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase Ib Phase II Advanced solid tumor Clear cell renal cancer Sunitinib plus / minus CVX-060</keyword>
</DOC>